Amplia Therapeutics Ltd. · ASX:ATX
Amplia Therapeutics — Bioshares Presentation July 2019
15 slides from Amplia Therapeutics's conference presentation, Jul 25, 2019
Slide 1: Amplia Therapeutics Limited - Bioshares Presentation July 2019
For personal use only Amplia Therapeutics Limited Bioshares Presentation - July 2019 ASX:ATX Amplifying Immuno-oncology
Slide 2: Notice
Notice For personal use only The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is made in
Slide 3: Amplia Therapeutics
Amplia Therapeutics For personal use only • A pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors offering therapeutic potential in cancer and fibrosis • Current focus is on highly selective FAK inhibitors o Combinations with immuno-oncology products o Wide range of
Slide 4: Checkpoint Inhibitor Primer
Checkpoint Inhibitor Primer For personal use only • Many cancers evade detection by the immune system by co-opting negative regulators of the anti-tumour immune response • One such immunosuppressive action is achieved by tumour upregulation of checkpoint proteins such as PD-L1 • Interaction of PD-L1
Slide 5: Checkpoint Inhibitor Market Growth
Checkpoint Inhibitor Market Growth For personal use only Annual Sales of Market Leading Checkpoint Inhibitors 16,000 14,000 12,000 USD $ ,000 10,000 8,000 6,000 4,000 2,000 0 2014 2015 2016 2017 2018 Keytruda (PD-1) Yervoy (CTLA-4) Opdivo (PD-1) Data assimilated from Bristol-Myers Squibb and Merck p
Slide 6: The Need
The Need For personal use only • Although checkpoint inhibitor drugs have revolutionised cancer treatment, complete response rates to these agents are still low • Only 44% of all cancer patients are eligible to receive these drugs and, of these, only 13% respond completely to therapy • Why do ~87% o
Slide 7: Focal Adhesion Kinase – a 'Bad Actor' in Cancer
Focal Adhesion Kinase – a ‘Bad Actor’ in Cancer For personal use only • FAK is upregulated in many cancers and plays multiple roles • Involved in cellular adhesion and migration • Promotes cancer cell survival and proliferation • Contributes to the establishment of an immunosuppressive tumour microe
Slide 8: Amplia's Therapeutic Focus
Amplia’s Therapeutic Focus For personal use only • Dual anti-fibrotic and immunomodulatory action of FAK inhibitors may be advantageous in fibrotic cancer • Growing case for potential of ‘mechanotherapeutics’ (including FAK inhibitors) in fibrotic cancers* • Fibrotic cancers including pancreatic and
Slide 9: Amplia's Early Clinical Development Strategy
Amplia’s Early Clinical Development Strategy For personal use only Phase 2 Phase 2 Phase 2 Phase 1 – Healthy volunteers • Establish clinical POC • Go as fast as possible • Cancer Preclinical Safety • Establish clinical safety baseline • Fibrosis • Confirm FAK engagement • Combinations • Establish sa
Slide 10: Amplia's Early Clinical Development Strategy
Amplia’s Early Clinical Development Strategy For personal use only • Perform first-in-human studies in healthy volunteers to establish a safety baseline • Assess safety, tolerability • Confirm engagement of FAK • Use established safety profile as a foundation for multiple combination opportunities •
Slide 11: High-level Development Plan (18 months)
High-level Development Plan (18 months) For personal use only In progress Phase 1 early 2020 IND / Phase 2 Ready end 2020 Cancer Indication Further Disease Phase 1 I-O Combo Trial (IND) AMP945 Models (I-O Focus) Enabling GLP Tox Healthy Volunteer Phase 1 (~50 pts) Fibrosis Indication AMP886 Disease
Slide 12: Competitive Landscape
Competitive Landscape For personal use only Agent Company Status Notes VS-4718 (PND-1186) Verastem P1 (various studies) First generation candidate P1 (NCT01335269) & BI-853520 Boehringer-Ingelheim Two trials completed (Aug 14 & Dec 15) (NCT01905111) Unknown status. Last update Mar 17. Single site Ch
Slide 13: Differentiation of Amplia FAK Assets
Differentiation of Amplia FAK Assets For personal use only • Excellent potency, selectivity and pharmacokinetics • AMP945 is a highly selective FAK inhibitor • AMP886 is a multi-action molecule that hits two other important cancer pathways – VEGFR3 and FLT3 • Strong intellectual property position •
Slide 14: Near Term Catalysts - Summary
Near Term Catalysts - Summary For personal use only • Amplia’s strategy is to position its assets to maximize opportunities for combination efficacy studies in cancer • Fibrosis indications further underpin value • Multiple near- and mid-term value inflection points • Phase 1 trial in healthy volunt
Slide 15: For personal use only
For personal use only Dr John Lambert Chief Executive Officer john@ampliatx.com +61 (0)409 525 259 www.ampliatx.com 5
Amplia Therapeutics — Bioshares Presentation July 2019 on 6ix